Seidman A D, Norton L, Reichman B S, Crown J P, Yao T J, Heelan R, Hakes T B, Lebwohl D E, Gilewski T A, Surbone A
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Semin Oncol. 1993 Aug;20(4 Suppl 3):40-5.
Single-agent paclitaxel (TAXOL) was administered to 79 patients with stage IV breast cancer. Twenty-eight patients had no prior chemotherapy (for metastatic disease), and 51 patients had extensive exposure to other chemotherapeutic agents before beginning the 24-hour paclitaxel infusion. Routine use of recombinant human granulocyte colony-stimulating factor helped to ameliorate neutropenia, the dose-limiting toxicity, in some cases. Other toxicity was generally mild to moderate. Paclitaxel was more active in patients whose stage IV disease had not yet been exposed to chemotherapy, but activity was seen in the patients previously treated extensively as well. There is a strong clinical suggestion of non-cross-resistance with doxorubicin. In one case, an excellent response in previously irradiated skin was seen. Paclitaxel is a very promising agent for the treatment of metastatic breast cancer.
对79例IV期乳腺癌患者使用了单药紫杉醇（泰素）进行治疗。28例患者此前未接受过（针对转移性疾病的）化疗，51例患者在开始24小时紫杉醇输注前曾广泛接触过其他化疗药物。常规使用重组人粒细胞集落刺激因子在某些情况下有助于改善作为剂量限制性毒性的中性粒细胞减少。其他毒性一般为轻度至中度。紫杉醇在IV期疾病尚未接受过化疗的患者中活性更高，但在之前接受过广泛治疗的患者中也可见活性。有强烈的临床迹象表明其与阿霉素不存在交叉耐药性。在1例患者中，此前接受过放疗的皮肤出现了显著反应。紫杉醇是治疗转移性乳腺癌的一种非常有前景的药物。
